# A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®

> **NCT00356421** · PHASE4 · TERMINATED · sponsor: **Pfizer** · enrollment: 58 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Inhaled Human Insulin (Exubera®)
- **DRUG:** Insulin lispro (Humalog)

## Key facts

- **NCT ID:** NCT00356421
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 58 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2009-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00356421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00356421, "A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00356421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*